KEGG   DRUG: Valsartan and cilnidipine
Entry
D10525            Mixture   Drug                                   
Name
Valsartan and cilnidipine;
Atedio (TN)
Component
Valsartan [DR:D00400], Cilnidipine [DR:D01173]
Class
Cardiovascular agent
 DG01925  Renin-angiotensin system inhibitor
 DG03231  Antihypertensive
Metabolizing enzyme substrate
 DG01639  CYP2C19 substrate
 DG01633  CYP3A/CYP3A4 substrate
  DG02913  CYP3A4 substrate
Remark
Therapeutic category: 2149
Product: D10525<JP>
Efficacy
Antihypertensive
Comment
Cilnidipine is metabolized by CYP3A4 with some contribution from CYP2C19.
Metabolism
Enzyme: CYP3A4 [HSA:1576]; CYP2C19 [HSA:1557]
Interaction
Brite
Therapeutic category of drugs in Japan [BR:br08301]
 2  Agents affecting individual organs
  21  Cardiovascular agents
   214  Antihypertensives
    2149  Others
     D10525  Valsartan and cilnidipine
Drug groups [BR:br08330]
 Cardiovascular agent
  DG01925  Renin-angiotensin system inhibitor
   D10525  Valsartan and cilnidipine
  DG03231  Antihypertensive
   D10525  Valsartan and cilnidipine
 Metabolizing enzyme substrate
  DG01639  CYP2C19 substrate
   D10525  Valsartan and cilnidipine
  DG01633  CYP3A/CYP3A4 substrate
   DG02913  CYP3A4 substrate
    D10525  Valsartan and cilnidipine
Drug classes [BR:br08332]
 Cardiovascular agent
  DG03231  Antihypertensive
   D10525  Valsartan and cilnidipine
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D10525
Other DBs
PubChem: 254741487
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system